Twitter

Archive for July 13th, 2012


NHS Cervical Cancer Screening Module 1

We worked with a group of leading clinical oncologists to develop a comprehensive program on screening for colon, breast, cervical, and prostate cancer. The message is aimed at general practitioners and their patients. This project is one of our largest undertakings so far. The cervical cancer CD-ROM alone features over 30 minutes of animation in a dual-audience, multi-media, multi-language educational program with a total runtime of over 3 hours. The CD-ROM is now being used by the UK’s National Health Service and has been distributed to over 10000 physicians.

Read More...

Brachytherapy for Prostate Cancer ~ Dr Michael Izard

Dr Michael Izard hosts a Q&A session on the topic of Brachytherapy for Prostate Cancer. Contact the Prostate Cancer Foundation of Australia for more information or to purchase this lecture on DVD. www.pcfa.org.au

Read More...

Skin Cancer Squamous Cell Carcinoma Keratoacanthoma Variant

Dr. Shane Chapman, MD discusses Skin Cancer Squamous Cell Carcinoma Keratoacanthoma Variant. See more at www.dermnet.com PLEASE RATE AND COMMENT!!! Keratoacanthomas appear suddenly and grow rapidly. They reach a certain size, usually 0.5 cm to 2.0 cm, stop growing, and then regress weeks to months later. They begin as red-to-flesh colored, dome-shaped papules with a smooth surface and a central crater filled with a keratinous plug. The pathologist sometimes has difficulty differentiating a keratoacanthoma from SCC. While keratoacanthomas have been regarded in the past as self-limited, regressing lesions that resemble squamous cell carcinoma, most dermatologists today would classify them as squamous cell carcinoma variants. They should be treated as other forms of squamous cell carcinoma.

Read More...

Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Condition :   Lymphoma Intervention :   Sponsors :   Guler, Nil, M.D.;   Nil Guler Completed – verified July 2012

Read More...

Hepatic Xenetix-CT Perfusion

Condition :   Hepatocellular Carcinoma Intervention :   Other: Xenetix-CT perfusion imaging Sponsors :   Guerbet;   Guerbet Recruiting – verified July 2012

Read More...

Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Thalagen™, a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

Condition :   Confirmed Diagnosis of ß-thalassemia Major Intervention :   Genetic: Autologous CD34+ cells transduced with TNS9.3.55 (Thalagen™) Sponsors :   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Errant Gene Therapeutics Recruiting – verified July 2012

Read More...

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Condition :   Malignant Neoplasm Interventions :   Drug: aprepitant;   Drug: palonosetron hydrochloride;   Drug: ondansetron;   Drug: dexamethasone Sponsors :   Ohio State University Comprehensive Cancer Center;   Rachel Layman Completed – verified July 2012

Read More...

Validating Pain Scales in Children and Young Adults

Conditions :   Solid Tumor;   Leukemia;   Neurofibromatosis Intervention :   Sponsors :   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI) Recruiting – verified June 2012

Read More...

HER2 Metastatic Breast Cancer Treatment

In this clip, Dr. David A. Margileth discusses the recent advances in treatment options for HER2 metastatic breast cancer patients and the various instances in which they may be used. He also goes on to mention some promising new drugs that are currently in clinical trials and have not yet reached the market. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor www.breastcanceranswers.com Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, www.breastcanceranswers.com This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

Read More...

Verastem, Inc. Discloses Research Results and Updated Clinical Plans…

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, hosted its annual Research and Development Day where Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board, gave a seminar on cancer stem cells.

Read More...